PRTAPROTHENA CORP PUBLIC LTD CO
Pharmaceutical Preparations
- Revenue
- $10M
- 93% YoY
- Operating margin
- -2216.4%
- 1838% YoY
- EBITDA
- −$214M
- 39% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired389% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $201M | $54M | $91M | $135M | $10M | 93% |
| Operating income | $72M | −$132M | −$191M | −$155M | −$215M | 39% |
| Net income | $67M | −$117M | −$147M | −$122M | −$244M | 100% |
| Operating cash flow | $93M | −$109M | −$134M | −$150M | −$164M | 9.0% |
| Stock-based comp | $25M | $31M | $41M | $46M | $38M | 18% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $8M · 10
- Open-market sells, 12 mo
- $0 · 0
- Net
- $8M
Pay vs performance
No pay-versus-performance disclosure yet.